OCWP
DNLI icon

Owl Creek Wealth Partners’s Denali Therapeutics DNLI Stock Holding History

Owl Creek Wealth Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Hold
450
– – ﹤0.01% 797
2026
Q1 		$8.64K Buy
+450
New +$8.95K ﹤0.01% 830

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Owl Creek Wealth Partners's DNLI Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 450 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #797.

Owl Creek Wealth Partners first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Owl Creek Wealth Partners held 450 shares of Denali Therapeutics worth $11.6K as of Q2 2026.
  • Owl Creek Wealth Partners left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #797 holding.
  • Owl Creek Wealth Partners first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.